- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- AZD5363 PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
| Phase 1 | Phase 2 | Phase 3 |
|---|
ASTX029
Selective Inhibitor of Extracellular Signal-Related Protein Kinases 1 and 2 (ERK 1/2)
| . |
Ownership: Astex
Mechanism of Action: Selective Inhibitor of Extracellular Signal-Related Protein Kinases 1 and 2 (ERK 1/2)
Indication: Advanced or Refractory Solid Tumors
How this therapy can help
The extracellular signal-related kinases 1 and 2 (ERK 1/2) are part of a key signalling pathway (the RAS-RAF-MEK-ERK pathway) activated in many tumor types including melanoma, lung, pancreatic and colorectal cancers. While inhibitors of RAF and MEK have been successfully developed and are now commercially available, to date no inhibitor of ERK is available commercially. Given the importance of this pathway in oncogenic signalling, ASTX029 has the potential, both as a single agent, and in combination with other therapies, to result in enhanced anti-tumor activity in a broad range of tumor types.
Clinical status
ASTX029 is currently being evaluated in a Phase 1/2 study in patients with advanced or refractory solid tumors to determine safety, pharmacokinetics and preliminary activity.